All News

The FDA approved margetuximab-cmkb (Margenza) in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received 2 or more prior anti-HER2 regimens, at least 1 of which was for metastatic disease.

The ongoing GO29365 study of combination regimens containing polatuzumab vedotin (Polivy) for patients with relapsed or refractory diffuse large B-cell lymphoma added an additional 106 patients to confirm preliminary findings of safety and efficacy.

At the 2020 SUO Meeting, Vikram M. Narayan, MD, spoke about the preliminary finds of his work with nadofaragene firadenovec.

This study demonstrated that the concurrent use of this new artificial intelligence tool alongside mammography improved the diagnostic performance of radiologists in the detection of breast cancer without prolonging their workflow.

The clinical researcher discussed areas of multiple myeloma which she believes deserve further assessment.

The pivotal phase 3 KEYNOTE-775/Study 309 trial evaluating the investigational use of pembrolizumab (Keytruda) plus lenvatinib (Lenvima) met its dual primary end points of overall and progression-free survival in patients with advanced endometrial cancer.

Research presented at the 2020 SABCS found providers planned to use neoadjuvant endocrine therapy for as little as possible until surgery was available for patients with estrogen receptor positive breast cancer.

This study revealed that reliability, or patient interpretation of telemedicine as a substitute for in-person visits, of the platform was of the greatest concern to all patients.

The agent was designed as an orphan drug for the treatment of pancreatic cancer, acute myeloid leukemia, myelodysplastic syndrome, peripheral T-cell lymphoma, Burkitt’s lymphoma, and soft tissue sarcoma.

Payne and colleagues indicated that a significant number of adolescent and young adult women are still not being given the information they desire regarding fertility preservation and therefore are not making fully informed treatment decisions.

Declan Murphy discusses the motivation behind the proPSMA study and the emerging history of PSMA PET/CT to challenge conventional imaging at the 2020 SUO Meeting.

Patients with aggressive lymphomas had a sharp increase in quality of life from time of diagnosis until 1 year later.

Data presented at SUO indicated that MK-6482 demonstrated durable efficacy in patients with Von Hippel-Lindau disease-associated clear cell renal cell carcinoma, pancreatic lesions, and hemangioblastomas by targeting the underlying pathophysiology of the disease.

The allogeneic off-the-shelf CD22-directed T-cell product, UCART22, showed early signs of activity and no evidence of unexpected toxicities for adult patients with relapsed/refractory CD22-positive B-cell acute lymphoblastic leukemia.

A recent study found a difference in preference when it came to the administration of rituximab in patients with blood cancer.

The hematology and oncology fellow at the Icahn School of Medicine at Mount Sinai highlighted multiple myeloma treatments that he believes have shown promise over the past year.

The GP2/GM-CSF combination demonstrated a 100% disease-free survival at 5 years for patients with HER2/neu 3–positive disease who received adjuvant trastuzumab.

For women with heavily pretreated, postmenopausal advanced or metastatic estrogen receptor (ER)–positive breast cancer, amcenestrant prompted antitumor activity.

The American Lung Association’s annual “State of Lung Cancer” (SOLC) report tracked the toll of lung cancer at national and state levels, identifying both promising improvements for the overall population and significant health disparities for racial and ethnic minorities.

The agency authorized use of the first coronavirus disease 2019 vaccine to prevent the disease caused by severe acute respiratory syndrome coronavirus 2 in individuals 16 years of age and older.

Neoadjuvant atezolizumab added to nab-paclitaxel followed by doxorubicin plus cyclophosphamide improved pathologic complete responses compared with placebo plus chemotherapy in patients with early triple-negative breast cancer without adding additional treatment burden.

Sacituzumab govitecan (Trodelvy) induced clinical benefit over physician’s choice of therapy in patients with metastatic triple-negative breast cancer, irrespective of Trop-2 expression, though greater efficacy was observed in those who had a medium or high Trop-2 score.

Frontline pembrolizumab (Keytruda) plus chemotherapy for patients with advanced triple-negative breast cancer showed efficacy across key subgroups, including patients with PD-L1 expression by combined positive score.

Treatment with ipatasertib plus paclitaxel (Abraxane) failed to show a significant improvement in progression-free survival versus placebo plus paclitaxel in patients with PIK3CA/AKT1/PTEN-altered locally advanced, unresectable, or metastatic triple-negative breast cancer.

The founder and CEO of Sema4 spoke about what health care providers currently lack in preventing and treating diseases and what the reality of early detection and disease prevention can provide to patients with cancer.

The clinical researcher spoke about what she hopes will occur in multiple myeloma research over the next 5 years.

The study found that favorable outcomes after treatment with lapatinib (Tykerb) were demonstrated by early declines in circulating tumor cell counts (CTCs) in patients with metastatic breast cancer who initially had HER2-negative primary tumors but positive HER2 CTCs.

Fewer deaths and improved cumulative incidence of central nervous system recurrences were shown at 8 years of follow-up with adjuvant neratinib (Nerlynx) compared with placebo in patients with early-stage HER2-positive breast cancer following trastuzumab (Herceptin)-based therapy.

Combination treatment with alpelisib (Piqray) and letrozole (Femara) sustained efficacy and did not result in any new safety signals in patients with PIK3CA-mutant HR-positive, HER2-negative advanced breast cancer who received prior treatment with the combination of a CDK4/6 inhibitor and fulvestrant (Faslodex).

Wolf discusses the potential for emerging next-generation CAR T-cell treatment and the future of treating patients with multiple myeloma.